Early ERCP is considered safe as well as cost-effective in the treatment of mild to moderate ascending cholangitis
Ascending cholangitis cost-effectiveness of therapy
Gallstone disease cost-effectiveness of therapy
Cholangitis cost-effectiveness of therapy
Ascending cholangitis future or investigational therapies
Spontaneous bacterial peritonitis cost-effectiveness of therapy
Ascending cholangitis medical therapy
Cirrhosis cost-effectiveness of therapy
Hepatocellular carcinoma cost-effectiveness of therapy